Clinical Trial Update: A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and immunogenicity of two doses of BG505 SOSIP.664 gp140 vaccine with adjuvant in adults who previously received BG505 SOS…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BG505 SOSIP.664 gp140 vaccine
• BG505 SOSIP.GT1.1 gp140 vaccine (recombinant HIV-1 envelope gp140 vaccine BG505 SOSIP.GT1.1)

Snippet

Sponsor: International AIDS Vaccine Initiative | Conditions: Hiv | Phase 1 | Status: ENROLLING_BY_INVITATION